The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

The case for Ozempic as a dementia buster is building. Research published this week has found that GLP-1 drugs are associated with a lower risk of dementia in people with type 2 diabetes.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Ozempic and Similar Drugs Could Help Ward Off Dementia, Study Suggests According to the study researchers, however, there’s still a lot we don’t know about exactly how GLP-1 drugs change ...

Drugs like Ozempic linked to 33% lower dementia risk To investigate, the scientists accessed data from Florida, Georgia, and Alabama. In total, this amounted to 92,160 people aged 50 or older with ...